Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer

Ciucci, Alessandra; Zannoni, Gian Franco; Travaglia, Daniele; Petrillo, Marco; Scambia, Giovanni; Gallo, Daniela

doi:10.1016/j.ygyno.2013.12.027

Cited by 57 publications

(65 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether the histology was a serous type nor non-serous type in the present study was not significantly different among these three groups in spite of the previous knowledge that suggested a better outcome in the serous type (Barlin et al, 2012). Ciucci et al recently reported that the anomalies of ERβ2 cytoplasmic expression in some serous types was an independent prognostic marker causing chemoresistance (Ciucci et al, 2014). Unfortunately, in the present study, we did not have any data of immunohistochemistry in these studied patients.…”

Section: Discussioncontrasting

confidence: 80%

Survival Outcomes of Recurrent Epithelial Ovarian Cancer: Experience from a Thailand Northern Tertiary Care Center

Jansaka

Suprasert²

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

To assess survival outcomes in a retrospective study, recurrent epithelial ovarian cancer patients were divided into three groups according to the platinum free interval as follows: platinum refractory that included the patients with tumor progression during treatment; platinum resistant and platinum sensitive that included the patients with tumor progression less than or more than six months, respectively. Clinical data for tumor progression in epithelial ovarian cancer patients treated at Chiang Mai University Hospital between January, 2006 and December, 2010 were reviewed. Thirty-nine patients were in the platinum refractory group while 27 were in the platinum resistant group and 75 in the platinum sensitive group. The mean age, the parity, the administration of neoadjuvant chemotherapy and the serous type did not significantly different across groups while the mean total number of chemotherapy regimens, the early stage patients, the patients with complete surgery and the surviving patients were significant more frequent in the platinum sensitive group. Regarding subsequent treatment after tumor recurrence, 87.2% underwent chemotherapy. With the median follow up time at 29 months, the median overall survival rates were 20 months, 14 months and 42 months in platinum refractory, platinum resistant and platinum sensitive groups, respectively (p<0.001). In addition, when the platinum sensitive patients developed the next episode of tumor progression, the median progression free interval time was only three to four months. In conclusion, the outcomes for platinum refractory the and platinum resistant groups was poorer than the platinum sensitive group. However, subsequent progression in the platinum sensitive group was also associated with a poor outcome.

show abstract

Section: Discussioncontrasting

confidence: 80%

Survival Outcomes of Recurrent Epithelial Ovarian Cancer: Experience from a Thailand Northern Tertiary Care Center

Jansaka

Suprasert²

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The expression of ER in general 38 and especially ERa has been associated with longer overall survival in ovarian cancer patients, 39 whereas the expression of ERb2 in advanced serous ovarian cancer has been associated with an unfavorable prognosis. 40 A recently published pooled analysis on the role of hormone receptors in ovarian cancer survival 38 evaluating tumors by histologic subtype showed no association between ER expression and survival in mucinous or low-grade serous carcinomas, both type I by definition. Recently it has been shown that ERa was expressed in both type I and type II tumors.…”

Section: Discussionmentioning

confidence: 99%

“…An incidence density sampling protocol was used, such that controls could include subjects who became a case later in time and each control could be sampled more than once. Cases and controls in both study phases were matched on: study recruitment center, age at blood donation (66 months), time of the day of blood collection (61 h), fasting status (<3 h, 3-6 h, >6 h), and menopausal status at blood collection (premenopausal, perimenopausal, postmenopausal), as well as menstrual cycle phase for premenopausal women ("early follicular" (days 0-7 of the cycle), "late follicular" (days 8-11), "peri-ovulatory" (days 12-16), "mid-luteal" (days [20][21][22][23][24], and "other luteal" (days 17-19 or days [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40]. Cases missing data on phase of menstrual cycle were matched to controls with missing information on menstrual cycle phase.…”

Section: Selection Of Case and Control Subjectsmentioning

confidence: 99%

Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition

et al. 2014

View full text Add to dashboard Cite

The role of endogenous androgens and sex hormone‐binding globulin (SHBG) in ovarian carcinogenesis is poorly understood. Epithelial invasive ovarian cancer (EOC) is a heterogeneous disease and there are no prospective data on endogenous androgens and EOC risk by tumor characteristics (histology, grade, stage) or the dualistic model of ovarian carcinogenesis (i.e. type I vs. type II, leading to less or more aggressive tumors). We conducted a nested case–control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort evaluating androgens and SHBG and invasive EOC risk by tumor characteristics. Female participants who provided a blood sample and were not using exogenous hormones at blood donation were eligible (n = 183,257). A total of 565 eligible women developed EOC; two controls (n = 1,097) were matched per case. We used multivariable conditional logistic regression models. We observed no association between androgens, SHBG and EOC overall. A doubling of androstenedione reduced risk of serous carcinomas by 21% (odds ratio (OR)log2 = 0.79, 95% confidence interval [CI] = [0.64–0.97]). Moreover, associations differed for low‐grade and high‐grade carcinomas, with positive associations for low‐grade and inverse associations for high‐grade carcinomas (e.g. androstenedione: low grade: ORlog2 = 1.99 [0.98–4.06]; high grade: ORlog2 = 0.75 [0.61–0.93], phet ≤ 0.01), similar associations were observed for type I/II tumors. This is the first prospective study to evaluate androgens, SHBG and EOC risk by tumor characteristics and type I/II status. Our findings support a possible role of androgens in ovarian carcinogenesis. Additional studies exploring this association are needed.

show abstract

“…Furthermore, cytoplasmic ERb2 expression was also reported to be associated with reduced 5-year survival and chemoresistance [47]. These novel findings suggest that ERb and its isoforms may have different roles and be associated with distinct prognosis depending on their cellular localization.…”

Section: Ers and Ovarian Cancermentioning

confidence: 77%

Estrogen receptor alpha and beta in health and disease

Jia

Dahlman-Wright

Gustafsson

2015

Best Practice & Research Clinical Endocrinology & Metab

400

331

View full text Add to dashboard Cite

Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer

Cited by 57 publications

References 35 publications

Survival Outcomes of Recurrent Epithelial Ovarian Cancer: Experience from a Thailand Northern Tertiary Care Center

Survival Outcomes of Recurrent Epithelial Ovarian Cancer: Experience from a Thailand Northern Tertiary Care Center

Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition

Estrogen receptor alpha and beta in health and disease

Contact Info

Product

Resources

About